Burchum & Rosenthal: Lehne's Pharmacology For Nursing Care, 9th Edition
Burchum & Rosenthal: Lehne's Pharmacology For Nursing Care, 9th Edition
Burchum & Rosenthal: Lehne's Pharmacology For Nursing Care, 9th Edition
Key Points
68-2
The information is used to (1) determine whether an outbreak is occurring, (2) evaluate
prevention and control strategies, and (3) evaluate the impact of national immunization
policies and practices.
Vaccines generally are very safe. Mild reactions are common, and serious events are rare.
Vaccinations can hurt. This pain, in turn, can lead to needle fears, procedural anxiety, and
avoidance of additional immunizations. Accordingly, minimizing pain is a primary goal.
Immunocompromised children are at special risk from live vaccines and should not
receive them.
Several large, high-quality studies conducted in Denmark, Britain, and the United States
have failed to show a causal link between childhood immunization using thimerosalcontaining vaccines and the development of autism.
The risk of serious adverse reactions can be minimized by observing appropriate
precautions and contraindications.
Absolute contraindications to vaccine administration in children include history of
anaphylactic reaction to a specific vaccine or vaccine component, as well as presence of
moderate or severe illnesses with or without a fever.
Practitioners are required to report certain adverse events to the Vaccine Adverse Event
Reporting System (VAERS). The information is used to help determine whether (1) a
particular event that occurs after vaccination is actually caused by the vaccine, and (2)
what the risk factors might be.
Key Points
68-3
Key Points
68-4
worldwide. Infection presents initially as upset stomach and vomiting, usually with fever,
and progresses to several days of diarrhea, which can be mild to severe. The combination
of vomiting and severe diarrhea can result in life-threatening dehydration. Virtually all
children become infected repeatedly within the first 5 years of life.
Human papillomavirus (HPV) infection is the cause of virtually all anogenital warts and
cervical cancers. Transmission occurs most often by direct genital contact during vaginal
or anal intercourse. The types of HPV that infect the anogenital region can also cause
cancers of the vulva, vagina, urethra, tongue, tonsils, penis, and anus.
Genital HPV is the most common sexually transmitted infection. In the United States,
about 6.2 million people become infected each year. Among sexually active males and
females, about 50% will be infected at some time during their life.
The chapter then presents information about the specific vaccines and toxoids, beginning with
measles, mumps, and rubella virus vaccine.
The chapter then discusses the diphtheria and tetanus toxoids and acellular
pertussis vaccines, followed by a discussion of the poliovirus vaccine.
Key Points
68-5
The chapter then provides information on the H. influenzae type b vaccine and the varicella
vaccine.
Hepatitis B vaccine (HepB) contains hepatitis B surface antigen (HBsAg), the primary
antigenic protein in the viral envelope. Administration of HepB promotes synthesis of
specific antibodies directed against hepatitis B virus.
HepB is one of the safest vaccines. The most common reactions are soreness at the
injection site and mild to moderate fever. Acetaminophen or ibuprofen may be used to
relieve discomfort, but aspirin should be avoided.
The only contraindication is a previous anaphylactic reaction either to HepB itself or to
bakers yeast.
All infants should receive monovalent HepB within 12 hours of birth. Infants whose
mothers are HBsAg positive should also receive hepatitis B immune globulin.
The hepatitis A vaccine is composed of inactivated hepatitis A viruses.
Key Points
68-6
HepA is extremely safe; mild adverse effects include soreness at the injection site and
headache.
The chapter then discusses the pneumococcal conjugate vaccine and meningococcal
conjugate vaccine.
In 2010, the U.S. Food and Drug Administration approved a 13-valent pneumococcal
conjugate vaccine (PCV13) for the prevention of invasive pneumococcal disease in
infants and children. An unconjugated vaccinepneumococcal polysaccharide vaccine
(PPV)also is available. However, PPV is approved only for adults and high-risk
children over the age of 2 years.
PCV13 appears very safe. No serious adverse effects have been reported. About 50% of
those vaccinated become drowsy after the shot, lose their appetite, or develop erythema
or tenderness at the injection site.
In the United States, two meningococcal conjugate polysaccharide vaccines (MCVs) are
usedMenactra, which was approved in 2005, and Menveo, which was approved in
2010. Both vaccines protect against the same four meningococcal serotypes (hence their
abbreviation, MCV4). The most common reactions are local pain, headache, and fatigue.
Local redness, swelling, and induration are also common.
Concerns that MCV4 might cause Guillain-Barr syndrome (GBS) appear to be
unfounded, as shown by two large studies. In one study, there were 99 confirmed cases of
GBS among 12,589,910 people vaccinated. In the other study, there were 5 cases among
889,684 people vaccinated. In both studies, the incidence of GBS was no higher than
would be expected in the absence of vaccination.
The chapter then discusses the influenza vaccine, the rotavirus vaccine, and the vaccine for
human papillomavirus.
Annual vaccination against influenza, including the H1N1 subtype, now is recommended
for all children between 6 months and 18 years of age.
In the United States, two rotavirus vaccines are availableRotaTeq, approved in 2006,
and Rotarix, approved in 2008. Both contain live, attenuated viruses. No serious adverse
effects were observed with RotaTeq. The safety of Rotarix appears comparable to that of
RotaTeq but with one important exception: postmarketing data show a small risk of
intussusception.
Rotarix (but not RotaTeq) is contraindicated for infants with any uncorrected congenital
malformation of the gastrointestinal (GI) tract that could predispose to intussusception.
Two HPV vaccines are available: Gardasil and Cervarix. These vaccines differ in
composition, indications, and immunogenicity. Gardasil protects against cervical, vulvar,
and vaginal cancer in females, as well as anal cancer and genital warts in females and
males. By contrast, Cervarix protects only against cervical cancer, but the protection may
last longer than with Gardasil.
Gardasil is used to prevent cancers, precancerous lesions, and genital warts in females
and males.
A Papanicolaou test (Pap test) still is needed, because Gardasil protects against only four
Key Points
68-7
types of HPV, leaving those vaccinated at risk of cervical cancer caused by other types of
HPV. Additionally, because Gardasil does not eliminate preexisting HPV infection, those
vaccinated remain at risk of cancer from an infection that was present before the vaccine
was given.
Gardasil appears to be very safe. Injection-site reactionspain, erythema, swelling, and
itchingalthough common, are mild and short lived. Fainting has occurred in teenage
girls, sometimes resulting in hospitalization.
Cervarix is designed to stimulate the production of neutralizing antibodies against two
types of HPVspecifically, types 16 and 18, which cause 70% of cervical cancers.
Cervarix is indicated only for the prevention of cervical cancers and precancerous lesions
caused by HPV types 16 and 18.
Because Cervarix does not confer 100% protection, vaccinated women should still have
routine Pap screening to allow early detection and treatment of precancerous lesions.
The most common local reactions with Cervarix are pain, redness, and swelling. The
most common systemic reactions are fatigue, headache, myalgia, GI symptoms,
arthralgia, fever, and rash.